Developing treatments as diverse as the disease itself¹

Cancer is one of the leading causes of death worldwide. With more than 100 types, it’s also one of the most complex diseases known to mankind.² Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020.³  By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.⁴

We aim to significantly improve the lives of cancer patients worldwide with approved therapies for a broad array of cancers.⁵

We have introduced innovative and breakthrough therapies for breast6, lung^7-9, genitourinary¹⁰ and haematology¹¹ cancers. Our current portfolio of oncology therapies covers a range of cancers. We continue to study these therapies alone and in combination with other treatments to fully explore their ability to improve the lives of cancer patients.⁵. Our robust pipeline includes biologics and immune-oncology agents that can change the treatment paradigm for a wide array of cancers.¹² These novel cancer medicines will help deliver meaningful breakthroughs that drive innovation and transform the cancer treatment landscape.⁵

Putting patients first

Globally, for more than 25 years, we have offered a number of assistance programs to help eligible patients access their prescription medicines. These programs have helped connect millions of patients to the medications they need.¹³

We work to ensure that our therapies can be accessed by a large group of patients. Our motto is: ‘Patients First’ and our patient support programs are designed to help patients across all social strata to ensure patient at all levels of society are included.

Our goal is to develop treatments that improve the lives of cancer patients around the world and ultimately reduce cancer's global impact.¹³

References:

1. ONCOLOGY BREAKTHROUGHS: THE LATEST IN CANCER RESEARCH. Available at: Oncology Research: Latest Cancer News and Breakthoughs | Pfizer (Accessed 23rd Sept 2021)
2. What Is Cancer? https://www.cancer.gov/about-cancer/understanding/what-is-cancer (Accessed 23rd Sept 2021)
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338. 
4. Cancer Statistics. https://www.cancer.gov/about-cancer/understanding/statistics (Accessed 23rd Sept 2021)
5. DISCOVER CANCER BREAKTHROUGHS. Discover Cancer Breakthroughs and Innovation | Pfizer | Pfizer (Accessed 23rd Sept 2021)
6. PFIZER’S PALBOCICLIB (PD-0332991) RECEIVES FOOD AND DRUG ADMINISTRATION BREAKTHROUGH THERAPY DESIGNATION FOR POTENTIAL TREATMENT OF PATIENTS WITH BREAST CANCER. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_palbociclib_pd_0332991_receives_food_and_drug_administration_breakthrough_therapy_designation
_for_potential_treatment_of_patients_with_breast_cancer (Accessed 23rd Sept 2021)
7. U.S. Food And Drug Administration Approves Pfizer’s XALKORI® (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer. Available at:
https://www.businesswire.com/news/home/20110826005815/en/U.S.-Food-And-Drug-Administration-Approves-Pfizer%E2%80%99s-XALKORI%C2%AE-crizotinib-As-First-And-Only-Therapy-Specifically-For-Patients-With-Locally-Advanced-Or-Metastatic-ALK-Positive-Non-Small-Cell-Lung-Cancer (Accessed 23rd Sept 2021)
8. FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer. available at: https://www.fda.gov/news-events/press-announcements/fda-expands-use-xalkori-treat-rare-form-advanced-non-small-cell-lung-cancer. (Accessed 23rd Sept 2021)
9. FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC. Available at: https://www.fda.gov/drugs/fda-approves-lorlatinib-second-or-third-line-treatment-alk-positive-metastatic-nsclc. (Accessed 23rd Sept 2021)
10. Pfizer's Sutent gets FDA approval for gastrointestinal and kidney cancer. Available online: https://www.thepharmaletter.com/article/pfizer-s-sutent-gets-fda-approval-for-gastrointestinal-and-kidney-cancer. (accessed on 22nd Sept 2021)
11. FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inotuzumab-ozogamicin-relapsed-or-refractory-b-cell-precursor-all. (accessed on 22nd Sept 2021)
12. CANCER DRUG DEVELOPMENT PIPELINE Oncology: Cancer Drug Pipeline and Clinical Trials | Pfizer (accessed on 22nd Sept 2021)
13. REDUCING CANCERS GLOBAL FOOTPRINT AND IMPACT. Cancer Global Footprint | Pfizer | Pfizer (accessed on 22nd Sept 2021)